MarketPulse

disease modification

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Levicept's Osteoarthritis Drug Shows NSAID-Comparable Results Ahead of Major Medical Conference

Levicept will present Phase II data for LEVI-04 at OARSI 2026, showing pain relief comparable to NSAIDs in 518-patient trial published in The Lancet.
PFEdisease modificationpain management
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cogent Biosciences Presents Expanded SUMMIT Trial Results for Bezuclastinib at 2026 AAAAI Meeting

Cogent Biosciences presented expanded SUMMIT trial data showing bezuclastinib achieved significant symptom reduction and tryptase normalization in systemic mastocytosis patients, supporting its FDA regulatory applications.
COGTdisease modificationclinical results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Touts Sustained Efficacy Data for Mast Cell Antibody Barzolvolimab

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.
CLDXbarzolvolimabchronic spontaneous urticaria